Company Overview and News

PNX Metals reveals high-grade lithium and lead-silver-gold in rock chips at Kilfoyle

PNX Metals Ltd’s (ASX:PNX) initial field visit to the newly acquired Kilfoyle Project in the Northern Territory has confirmed high-grade lithium and lead-silver-gold in surface rock chip samples.

PNX Metals' James Fox details near-mine and regional exploration program with investors

PNX Metals Ltd (ASX:PNX) managing director, James Fox, presented to investors at Proactive's CEO Sessions this week in Melbourne and Sydney.

PNX Metals drilling prospects near Hayes Creek Project as DFS continues

PNX Metals Ltd (ASX:PNX) managing director and CEO James Fox speaks to Proactive Investors about the multi-commodity exploration and development company's Northern Territory operations. The company is focused on the development of its flagship Hayes Creek zinc-gold-silver project, and exploration at a number of neighbouring sites.

PNX Metals wins co-funding to drill for nickel-copper-cobalt

PNX Metals Ltd (ASX:PNX) is gearing up to test for potential nickel-copper-cobalt sulphide mineralisation at its Kilfoyle Project in the Northern Territory.

PNX Metals commences gold drilling at Fountain Head

PNX Metals Ltd (ASX:PNX) has commenced drilling activities at the recently acquired Fountain Head mineral leases nearby to the Hayes Creek Project in the Northern Territory.

PNX Metals does farm-in deal for multi-commodity project in Northern Territory

PNX Metals Ltd (ASX:PNX) has signed a binding term sheet to acquire via farm-in a 90% interest in the Kilfoyle Project located 130 kilometres south-southwest of Darwin, Northern Territory.

PNX Metals about to drill gold and base metal targets near Hayes Creek development project

PNX Metals Ltd (ASX:PNX) is about to begin an extensive near-mine and regional exploration program for gold and base metals in the Pine Creek Orogen of the Northern Territory.

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to ASX:PNX / PNX METALS LIMITED on message board site Silicon Investor.

FPNX - Pacific First Networks Inc. FPNX - First Pacific Networks